Document Detail


Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes.
MedLine Citation:
PMID:  21907210     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Myocardial infarction (MI) is one of the leading causes of morbidity and mortality world-wide. Whether endogenous repair and regenerative ability could be augmented by drug administration is an important issue for generation of novel therapeutic approach. Recently it was reported that in mice pretreated with thymosin beta 4 (TB4) and subsequently subjected to experimental MI, a subset of epicardial cells differentiated into cardiomyocytes. In clinical settings, epicardial priming with TB4 prior to MI is impractical. Here we tested if TB4 treatment after MI could reprogram epicardium into cardiomyocytes and augment the epicardium's injury response. Using epicardium genetic lineage trace line Wt1(CreERT2/+) and double reporter line Rosa26(mTmG/+), we found post-MI TB4 treatment significantly increased the thickness of epicardium and coronary capillary density. However, epicardium-derived cells did not adopt cardiomyocyte fate, nor did they migrate into myocardium to become coronary endothelial cells. Our result thus indicates that TB4 treatment after MI does not alter epicardial cell fate to include the cardiomyocyte lineage, providing both cautions and insights for the full exploration of the potential benefits of TB4 in the clinical settings. This article is part of a Special Issue entitled 'Possible Editorial'.
Authors:
Bin Zhou; Leah B Honor; Qing Ma; Jin-Hee Oh; Ruei-Zeng Lin; Juan M Melero-Martin; Alexander von Gise; Pingzhu Zhou; Tianyuan Hu; Lingjuan He; Kai Hong Wu; Hui Zhang; Yuebo Zhang; William T Pu
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-08-26
Journal Detail:
Title:  Journal of molecular and cellular cardiology     Volume:  52     ISSN:  1095-8584     ISO Abbreviation:  J. Mol. Cell. Cardiol.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-26     Completed Date:  2012-04-24     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  0262322     Medline TA:  J Mol Cell Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  43-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Affiliation:
Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. zhoubin@sibs.ac.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Differentiation / drug effects
Mice
Myocardial Infarction / drug therapy*,  metabolism
Myocytes, Cardiac / cytology*,  drug effects*
Pericardium / cytology*,  drug effects*
Thymosin / pharmacology*,  therapeutic use*
Grant Support
ID/Acronym/Agency:
K08 HL004387/HL/NHLBI NIH HHS; R01 HL094683/HL/NHLBI NIH HHS; R01 HL094683/HL/NHLBI NIH HHS; U01 HL100401/HL/NHLBI NIH HHS; U01 HL100401/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
61512-21-8/Thymosin; 77591-33-4/thymosin beta(4)
Comments/Corrections
Comment In:
J Mol Cell Cardiol. 2012 Jan;52(1):10-2   [PMID:  22019445 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathogen-associated molecular pattern-induced mitochondrial membrane depolarization in the earthworm...
Next Document:  Reduction of Boolean network models.